NO20054425L - Heteroarylkarbamoylbenzenderivater - Google Patents

Heteroarylkarbamoylbenzenderivater

Info

Publication number
NO20054425L
NO20054425L NO20054425A NO20054425A NO20054425L NO 20054425 L NO20054425 L NO 20054425L NO 20054425 A NO20054425 A NO 20054425A NO 20054425 A NO20054425 A NO 20054425A NO 20054425 L NO20054425 L NO 20054425L
Authority
NO
Norway
Prior art keywords
formula
ring
substituent
group
oxygen
Prior art date
Application number
NO20054425A
Other languages
English (en)
Norwegian (no)
Inventor
Teruyuki Nishimura
Jun-Ichi Eiki
Tomoharu Iino
Noriaki Hashimoto
Hiroshi Nakashima
Keiji Takahashi
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of NO20054425L publication Critical patent/NO20054425L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054425A 2003-02-26 2005-09-23 Heteroarylkarbamoylbenzenderivater NO20054425L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003049466 2003-02-26
JP2003400882 2003-11-28
JP2004031298 2004-02-06
PCT/JP2004/002284 WO2004076420A1 (fr) 2003-02-26 2004-02-26 Derives d'heteroarylcarbamoylbenzene

Publications (1)

Publication Number Publication Date
NO20054425L true NO20054425L (no) 2005-09-23

Family

ID=32931126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054425A NO20054425L (no) 2003-02-26 2005-09-23 Heteroarylkarbamoylbenzenderivater

Country Status (16)

Country Link
US (2) US7432287B2 (fr)
EP (1) EP1600442B1 (fr)
JP (1) JP4432901B2 (fr)
KR (1) KR20050105488A (fr)
CN (1) CN101712657A (fr)
AU (1) AU2004215514B2 (fr)
BR (1) BRPI0407810A (fr)
CA (1) CA2516407C (fr)
EC (1) ECSP055987A (fr)
MA (1) MA27660A1 (fr)
MX (1) MXPA05009059A (fr)
NO (1) NO20054425L (fr)
NZ (1) NZ541824A (fr)
RU (1) RU2330030C2 (fr)
UA (1) UA81468C2 (fr)
WO (1) WO2004076420A1 (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
US7728025B2 (en) * 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
JP2007523905A (ja) * 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
EP2048137A1 (fr) * 2004-02-18 2009-04-15 AstraZeneca AB Dérivés de la benzamide et leur utilisation comme activateurs de la glucokinase.
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
BRPI0516595A (pt) * 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
ES2476840T3 (es) * 2005-03-04 2014-07-15 F. Hoffmann-La Roche Ag Derivados de piridina-2-carboxamida como antagonistas de MGLUR5
EP1891069A1 (fr) * 2005-05-24 2008-02-27 AstraZeneca AB Derives d'imidazol[4,5b]pyridine/pyrazine et purine substitues en 2-phenyl en tant que modulateurs de la glucokinase
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
RU2415141C2 (ru) * 2005-07-09 2011-03-27 Астразенека Аб Производные гетероарилбензамида для применения в качестве активаторов glk в лечении диабета
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
GB0514173D0 (en) * 2005-07-09 2005-08-17 Astrazeneca Ab Chemical compounds
WO2007017649A1 (fr) * 2005-08-09 2007-02-15 Astrazeneca Ab Dérivés hétéroarylcarbamoylbenzène pour traiter le diabète
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1928874A1 (fr) * 2005-09-16 2008-06-11 AstraZeneca AB Composés hétérobicycliques utilisés comme activateurs de la glucokinase
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
JP4990783B2 (ja) * 2005-09-30 2012-08-01 Ｍｓｄ株式会社 ２−ヘテロアリール置換インドール誘導体
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
BRPI0616865A2 (pt) 2005-10-05 2011-07-05 Hoffmann La Roche compostos derivados de naftiridina, processo para preparação dos mesmos, medicamentos e uso dos mesmos
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
EP2001875A2 (fr) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Activateurs de la glucokinase
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (fr) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Derives de l'indazole et de l'isoindazole comme agents de l'activation de glucokinase
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
JP2009544648A (ja) * 2006-07-24 2009-12-17 エフ．ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化剤としてのピラゾール類
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) * 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
CN101563330B (zh) * 2006-10-26 2012-06-27 阿斯利康(瑞典)有限公司 作为葡糖激酶(glk)激活剂的苯甲酰氨基杂环化合物
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
MX2009006729A (es) * 2006-12-21 2009-08-07 Astrazeneca Ab Nuevo compuesto cristalino util como activador de glk.
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
WO2008084872A1 (fr) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation Dérivé d'hydrazone
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
WO2008116107A2 (fr) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Activateurs de glucokinase
JP2010138073A (ja) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
EP2178852B9 (fr) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Composés thiazolide à substitution alkylsulfonyle
CA2695583A1 (fr) 2007-08-13 2009-02-19 Metabasis Therapeutics, Inc. Nouveaux activateurs de glucokinase
AR068540A1 (es) * 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.
JP5457358B2 (ja) * 2007-10-09 2014-04-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコキナーゼアクチベーターとしてのｎ−（ピラゾール−３−イル）−ベンズアミド誘導体
KR20100090250A (ko) * 2007-10-09 2010-08-13 메르크 파텐트 게엠베하 글루코키나제 활성체로서 유용한 피리딘 유도체
AU2008321959B2 (en) 2007-11-12 2014-02-13 Msd K.K. Heteroaryloxy quinazoline derivative
JPWO2009081782A1 (ja) * 2007-12-25 2011-05-06 萬有製薬株式会社 Ｎ−ピラゾール−２−ピリジンカルボキサミド誘導体
CN102015637B (zh) * 2008-02-06 2014-05-21 第一三共株式会社 苯基吡咯衍生物
EP2245025A1 (fr) * 2008-02-27 2010-11-03 Merck Patent GmbH Dérivés d'hétéroaryl-carboxamides utilisés pour le traitement du diabète
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
JP2012500181A (ja) 2008-08-15 2012-01-05 Ｍｓｄ株式会社 アセチルピロリジニルインドール誘導体
CA2734981A1 (fr) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co., Ltd. Derive d'oxotetrahydrofurann-2-yl-benzimidazole
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
UA104742C2 (uk) * 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
WO2010082601A1 (fr) * 2009-01-16 2010-07-22 第一三共株式会社 Nouveau dérivé de pyrrole 2,5-disubstitué
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010103437A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
WO2010107610A1 (fr) * 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Méthode de traitement du diabète et des états pathologiques correspondants par thérapie combinatoire et compositions contenant de tels composés
WO2010116176A1 (fr) * 2009-04-09 2010-10-14 Astrazeneca Ab Dérivé de pyrazolo [4, 5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
CA2768577A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase
EP2459554B1 (fr) 2009-07-31 2013-09-18 Cadila Healthcare Limited Dérivés de benzamide substitués utiles comme activateurs de la glucokinase (gk)
BR112012016025A2 (pt) * 2009-12-11 2018-11-06 Astellas Pharma Inc. composto de benzamida
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011095997A1 (fr) * 2010-02-08 2011-08-11 Advinus Therapeutics Private Limited Composés de benzamide à titre d'activateurs de glucokinase et leur application pharmaceutique
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2011158149A1 (fr) * 2010-06-18 2011-12-22 Pfizer Inc. Dérivés de 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one
US9000154B2 (en) * 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
CN106349138A (zh) * 2011-06-02 2017-01-25 奇诺因私人有限公司 用于制备前列腺素酰胺的新的方法
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
CA2870488A1 (fr) 2012-04-16 2013-10-24 Kaneq Pharma Inc. Derives de phosphonates aromatiques fusionnes utilises comme precurseurs d'inhibiteurs de ptp-1b
IN2014DN09554A (fr) 2012-05-17 2015-07-17 Transtech Pharma Llc
CN109715637B (zh) * 2016-07-22 2022-04-05 百时美施贵宝公司 葡萄糖激酶激活剂及其使用方法
WO2019023651A2 (fr) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology Modulateurs du récepteur des androgènes à petite molécule
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CA3093025A1 (fr) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Utilisations therapeutiques d'activateurs de glucokinase en combinaison avec de l'insuline ou des analogues d'insuline
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
CN113527146B (zh) * 2021-08-19 2023-04-18 广东药科大学 分子氧促进谐二氟烯烃羟化磺酰酯化反应制备β-羟基-谐二氟磺酰酯类化合物的方法
CN121712503A (zh) * 2023-06-16 2026-03-20 康特克斯生物科技美国公司 稠合二环杂环或杂芳基酰胺化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3091392A (en) 1991-12-11 1993-07-19 Sasol Chemicals Europe Limited Method to produce single cell oil containing gamma-linolenic acid
GB9725298D0 (en) * 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
US6268387B1 (en) * 1997-12-23 2001-07-31 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003080585A1 (fr) * 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Derive aminobenzamide
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
JP2007523905A (ja) * 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
EP2048137A1 (fr) * 2004-02-18 2009-04-15 AstraZeneca AB Dérivés de la benzamide et leur utilisation comme activateurs de la glucokinase.

Also Published As

Publication number Publication date
CA2516407C (fr) 2013-07-09
JPWO2004076420A1 (ja) 2006-06-01
BRPI0407810A (pt) 2006-03-01
NZ541824A (en) 2010-04-30
HK1091204A1 (zh) 2007-01-12
JP4432901B2 (ja) 2010-03-17
CA2516407A1 (fr) 2004-09-10
AU2004215514B2 (en) 2010-03-04
UA81468C2 (en) 2008-01-10
WO2004076420A1 (fr) 2004-09-10
EP1600442A4 (fr) 2006-11-02
US7754743B2 (en) 2010-07-13
KR20050105488A (ko) 2005-11-04
CN101712657A (zh) 2010-05-26
MXPA05009059A (es) 2005-10-19
US20060167053A1 (en) 2006-07-27
EP1600442B1 (fr) 2018-01-17
RU2005129729A (ru) 2006-03-20
US7432287B2 (en) 2008-10-07
RU2330030C2 (ru) 2008-07-27
AU2004215514A1 (en) 2004-09-10
EP1600442A1 (fr) 2005-11-30
US20090018056A1 (en) 2009-01-15
MA27660A1 (fr) 2005-12-01
ECSP055987A (es) 2006-01-16

Similar Documents

Publication Publication Date Title
UA81468C2 (en) Heteroarylcarbamoylbenzene derivatives
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
EA200970172A1 (ru) Пролекарство соединения амида коричной кислоты
NO20054885L (no) 3-alkylidenhydrazino substituerte heteroarylforbindelser som trombopoietin reseptor aktivator
NO20053614L (no) Nye pyridazin-3(2H)-on-derivater
SG169900A1 (en) 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
NO20033848L (no) Nitrogenholdige heteroarylforbindelser med en HIV integrase inhiberende aktivitet
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
ES2305452T3 (es) Inhibidores de la catepsina cisteina y proteasa.
WO2005028445A3 (fr) Urees heteroaromatiques modulant la fonction du recepteur vanilloiode-1 (vr1)
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
NO20051270L (no) Sammensmeltet benzenderivat og anvendelse
NO20064004L (no) Virale polymeraseinhibitorer
NZ509045A (en) Intermediates in the formation of antivirally active heterocyclic azahexane derivatives
NO20075650L (no) Tri- eller tetrasubstituterte 3-aminopyrrolidinderivater
NO20060142L (no) Syklisk tertiaer aminforbindelse
MX2010002338A (es) Compuesto de organoazufre con fluor y composicion pesticida que lo comprende.
AU2003285584A8 (en) 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
NO20063090L (no) Amidopyrazolderivater
WO2003035620A1 (fr) Compose bicyclique
MY140749A (en) Novel piperidine compound
MY148980A (en) Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
NO20063989L (no) Fremgangsmater for a produsere 3-O-beskyttede morfinoner og 3-O-beskyttede morfinondienol-karboksylater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application